Carbohydrate metabolism disorders at Cushing disease onset

Main Article Content

N.O. Pertseva
T.V. Chursinova


Atypical forms of endogenous hypercorticism, which are manifested in non-specific symptoms such as arterial hypertension, diabetes mellitus, obesity, are increasingly common in clinical practice to date. Considering that patients with hypercorticism have high risk of cardiovascular mortality, timely diagnosis is important. The clinical case was presented when Cushing disease manifested itself in the development of diabetes mellitus, arterial hypertension, rapid weight gain and no skin symptoms. Timely surgical treatment led to a complete regression of diabetes mellitus, normalization of blood pressure and weight of the patient.

Article Details

How to Cite
Pertseva, N., and T. Chursinova. “Carbohydrate Metabolism Disorders at Cushing Disease Onset”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 16, no. 2, Mar. 2020, pp. 93-97, doi:10.22141/2224-0721.16.2.2020.201292.
Original Researches


Hirsch D, Shimon I, Manisterski Y, et al. Cushing's syndrome: comparison between Cushing's disease and adrenal Cushing's. Endocrine. 2018;62(3):712–720. doi:10.1007/s12020-018-1709-y.

Bertagna X. Management of endocrine disease: Can we cure Cushing's disease? A personal view. Eur J Endocrinol. 2018;178(5):R183–R200. doi:10.1530/EJE-18-0062.

Pankiv VI. Cushing’s disease: diagnosis, clinic, treatment. Mìžnarodnij endokrinologìčnij žurnal. 2011;(37):159-167. (in Ukrainian).

Catargi B, Rigalleau V, Poussin A, et al. Occult Cushing's syndrome in type-2 diabetes. J Clin Endocrinol Metab. 2003;88(12):5808–5813. doi:10.1210/jc.2003-030254.

Clayton RN, Jones PW, Reulen RC, et al. Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol. 2016;4(7):569–576. doi:10.1016/S2213-8587(16)30005-5.

Faggiano A, Pivonello R, Spiezia S, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab. 2003;88(6):2527–2533. doi:10.1210/jc.2002-021558.

Feelders RA, Pulgar SJ, Kempel A, Pereira AM. The burden of Cushing's disease: clinical and health-related quality of life aspects. Eur J Endocrinol. 2012;167(3):311–326. doi:10.1530/EJE-11-1095.

Most read articles by the same author(s)